Mucosal antibodies to the C terminus of toxin A prevent colonization of Clostridium difficile

Infection and Immunity

Volumn 85, Issue 4, 2017, Pages

  Hong, Huynh A ^a   Hitri, Krisztina ^a   Hosseini, Siamand ^a   Kotowicz, Natalia ^a   Bryan, Donna ^b   Mawas, Fatme ^b   Wilkinson, Anthony J ^c   van Broekhoven, Annie ^d   Kearsey, Jonathan ^e   Cutting, Simon M ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d Q Biologicals BioIncubator   (Belgium)

^e Leads to Development   (France)

Author keywords

Clostridium difficile; Colonization; Immune exclusion; Mucosal immunity; Oral vaccines

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; DEHYDROGENASE ADHE1; DEHYDROGENASE LDHA; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OXIDOREDUCTASE; PROTEIN CDEC; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TOXIN ANTIBODY; TOXOID; TOXOID A; TOXOID B; UNCLASSIFIED DRUG; BACTERIAL TOXIN; BACTERIUM ANTIBODY; ENTEROTOXIN; PEPTIDE FRAGMENT; SECRETORY IMMUNOGLOBULIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; BACILLUS SUBTILIS; BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL SPORE; BACTERIAL STRAIN; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CROSS REACTION; HAMSTER; HUMAN; HUMAN CELL; INTESTINE CELL; MICROBIAL ADHESION; MOUSE; MUCOSAL IMMUNITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION; ANIMAL; CELL LINE; CHEMISTRY; CLOSTRIDIUM INFECTIONS; IMMUNIZATION; IMMUNOLOGY; MICROBIOLOGY; MUCOSA; PROTEIN DOMAIN;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; CELL LINE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CRICETINAE; CROSS REACTIONS; ENTEROTOXINS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; MICE; MUCOUS MEMBRANE; PEPTIDE FRAGMENTS; PROTEIN INTERACTION DOMAINS AND MOTIFS; SPORES, BACTERIAL;

EID: 85016183400     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01060-16     Document Type: Article

References (38)

1. Kelly CP, LaMont JT. 2008. Clostridium difficile-more difficult than ever. N Engl J Med 359:1932-1940. https://doi.org/10.1056/NEJMra0707500.
2. Dobson G, Hickey C, Trinder J. 2003. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med 29:1030. https://doi.org/10.1007/s00134-003-1754-7.
3. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. 2016. Clostridium difficile infection. Nat Rev Dis Primers 2:16020. https://doi.org/10.1038/nrdp.2016.20.
4. Shen A. 2012. Clostridium difficile toxins: mediators of inflammation. J Innate Immun 4:149-158. https://doi.org/10.1159/000332946.
5. Gerding DN, Muto CA, Owens RC, Jr. 2008. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 46(Suppl 1):S43-S49. https://doi.org/10.1086/521861.
6. Martin JS, Monaghan TM, Wilcox MH. 2016. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol 13:206-216. https://doi.org/10.1038/nrgastro.2016.25.
7. Lawley TD, Clare S, Walker AW, Goulding D, Stabler RA, Croucher N, Mastroeni P, Scott P, Raisen C, Mottram L, Fairweather NF, Wren BW, Parkhill J, Dougan G. 2009. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 77: 3661-3669. https://doi.org/10.1128/IAI.00558-09.
8. Kelly CP, Kyne L. 2011. The host immune response to Clostridium difficile. J Med Microbiol 60:1070-1079. https://doi.org/10.1099/jmm.0.030015-0.
9. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. 2010. The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711-713. https://doi.org/10.1038/nature09397.
10. Ghose C, Kelly CP. 2015. The prospect for vaccines to prevent Clostridium difficile infection. Infect Dis Clin North Am 29:145-162. https://doi.org/10.1016/j.idc.2014.11.013.
11. Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H. 2013. Systemic antibody responses induced by a twocomponent Clostridium difficile toxoid vaccine protect against C. difficileassociated disease in hamsters. J Med Microbiol 62:1394-1404. https://doi.org/10.1099/jmm.0.056796-0.
12. Kociolek LK, Gerding DN. 2016. Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol 13:150-160. https://doi.org/10.1038/nrgastro.2015.220.
13. Spigaglia P, Barbanti F, Mastrantonio P, European Study Group on Clostridium difficile. 2011. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 66:2227-2234. https://doi.org/10.1093/jac/dkr292.
14. Tenover FC, Tickler IA, Persing DH. 2012. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother 56:2929-2932. https://doi.org/10.1128/AAC.00220-12.
15. Spigaglia P. 2016. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis 3:23-42. https://doi.org/10.1177/2049936115622891.
16. Debast SB, van Leengoed LA, Goorhuis A, Harmanus C, Kuijper EJ, Bergwerff AA. 2009. Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environ Microbiol 11:505-511. https://doi.org/10.1111/j.1462-2920.2008.01790.x.
17. Rupnik M, Widmer A, Zimmermann O, Eckert C, Barbut F. 2008. Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J Clin Microbiol 46:2146. https://doi.org/10.1128/JCM.00598-08.
18. Tvede M, Rask-Madsen J. 1989. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet i:1156-1160.
19. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S. 2015. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313:1719-1727. https://doi.org/10.1001/jama.2015.3725.
20. Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. 2012. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 56:5224-5229. https://doi.org/10.1128/AAC.00913-12.
21. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. 2002. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186:1781-1789. https://doi.org/10.1086/345676.
22. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM. 2011. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun 79: 2295-2302. https://doi.org/10.1128/IAI.00130-11.
23. Bungiro RD, Jr, Sun T, Harrison LM, Shoemaker CB, Cappello M. 2008. Mucosal antibody responses in experimental hookworm infection. Parasite Immunol 30:293-303. https://doi.org/10.1111/j.1365-3024.2008.01023.x.
24. Corthesy B. 2009. Secretory immunoglobulin A: well beyond immune exclusion at mucosal surfaces. Immunopharmacol Immunotoxicol 31: 174-179. https://doi.org/10.1080/08923970802438441.
25. Barra-Carrasco J, Olguin-Araneda V, Plaza-Garrido A, Miranda-Cardenas C, Cofre-Araneda G, Pizarro-Guajardo M, Sarker MR, Paredes-Sabja D. 2013 The Clostridium difficile exosporium cysteine (CdeC)-rich protein is required for exosporium morphogenesis and coat assembly. J Bacteriol 195:3863-3875. https://doi.org/10.1128/JB.00369-13.
26. Redmond C, Baillie LW, Hibbs S, Moir AJ, Moir A. 2004. Identification of proteins in the exosporium of Bacillus anthracis. Microbiology 150: 355-363. https://doi.org/10.1099/mic.0.26681-0.
27. Lesuffleur T, Barbat A, Dussaulx E, Zweibaum A. 1990. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucussecreting cells. Cancer Res 50:6334-6343.
28. Wijburg OL, Uren TK, Simpfendorfer K, Johansen FE, Brandtzaeg P, Strugnell RA. 2006. Innate secretory antibodies protect against natural Salmonella typhimurium infection. J Exp Med 203:21-26. https://doi.org/10.1084/jem.20052093.
29. Dawson LF, Valiente E, Faulds-Pain A, Donahue EH, Wren BW. 2012. Characterisation of Clostridium difficile biofilm formation, a role for Spo0A. PLoS One 7:e50527. https://doi.org/10.1371/journal.pone.0050527.
30. Kutzenko AS, Lamzin VS, Popov VO. 1998. Conserved supersecondary structural motif in NAD-dependent dehydrogenases. FEBS Lett 423: 105-109. https://doi.org/10.1016/S0014-5793(98)00074-X.
31. Mantis NJ, Rol N, Corthesy B. 2011. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 4:603-611. https://doi.org/10.1038/mi.2011.41.
32. Apter FM, Michetti P, Winner LS, III, Mack JA, Mekalanos JJ, Neutra MR. 1993 Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect Immun 61:5279-5285.
33. Jagadeesan B, Koo OK, Kim KP, Burkholder KM, Mishra KK, Aroonnual A, Bhunia AK. 2010. LAP, an alcohol acetaldehyde dehydrogenase enzyme in Listeria, promotes bacterial adhesion to enterocyte-like Caco-2 cells only in pathogenic species. Microbiology 156:2782-2795. https://doi.org/10.1099/mic.0.036509-0.
34. Semenyuk EG, Laning ML, Foley J, Johnston PF, Knight KL, Gerding DN, Driks A. 2014. Spore formation and toxin production in Clostridium difficile biofilms. PLoS One 9:e87757. https://doi.org/10.1371/journal.pone.0087757.
35. Colenutt C, Cutting SM. 2014. Use of Bacillus subtilis PXN21 spores for suppression of Clostridium difficile infection symptoms in a murine model. FEMS Microbiol Lett 358:154-161. https://doi.org/10.1111/1574-6968.12468.
36. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. 2014. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 39:579-594. https://doi.org/10.1111/apt.12639.
37. Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson JL. 1990. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun 58:480-488.
38. Wust J, Sullivan NM, Hardegger U, Wilkins TD. 1982. Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol 16:1096-1101.